Intravitreal GD2-Specific Chimeric Antigen Receptor T-Cell Therapy for Refractory Retinoblastoma - PubMed
8 hours ago
- #CAR T-cell therapy
- #refractory retinoblastoma
- #immunotherapy
- Study evaluates intravitreal GD2-specific CAR T-cell therapy for refractory retinoblastoma.
- Patient received two injections; localized ocular inflammation occurred and subsided after each.
- Elevated intraocular pressure led to enucleation at six weeks post-treatment.
- Histopathology showed dense peritumoral lymphocytic infiltration without anterior segment involvement.
- Therapy was feasible, well-tolerated, and induced immune activation and tumor regression.